<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00071487</url>
  </required_header>
  <id_info>
    <org_study_id>LBSL02</org_study_id>
    <nct_id>NCT00071487</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)</brief_title>
  <official_title>A Phase 2, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Efficacy of LymphoStat-B™ Antibody (Monoclonal Anti-BLyS Antibody) in Subjects With Systemic Lupus Erythematosus (SLE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Human Genome Sciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Human Genome Sciences Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of 3 different doses of
      belimumab, administered in addition to standard therapy, in patients with active SLE disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of three different doses of
      belimumab (1 mg/kg, 4 mg/kg, and 10 mg/kg), administered in addition to standard therapy,
      compared to placebo plus standard therapy in patients with active SLE disease. Patients were
      randomly assigned, following stratification by the screening SELENA SLEDAI score (4 to 7
      versus ≥ 8), to 1 of the 4 study arms (3 active arms and 1 placebo arm plus standard therapy
      for SLE). All patients were to be dosed on Days 0, 14, and 28, then every 28 days for the
      remainder of 52 weeks. Patients completing the 52-week period could enter a 24-week
      open-label extension; belimumab patients received the same dose or were switched to 10 mg/kg
      at the investigator's discretion and former placebo patients received belimumab 10 mg/kg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change From Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24.</measure>
    <time_frame>Baseline, 24 weeks</time_frame>
    <description>SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to First Mild/Moderate or Severe SLE Flare (SLE Flare Index)</measure>
    <time_frame>0 to 52 weeks</time_frame>
    <description>The SLE Flare Index categorized SLE flare as &quot;mild or moderate&quot; or &quot;severe&quot; based on 5 variables: 1) change in SELENA SLEDAI score from the most recent assessment to current, 2) change in signs or symptoms of disease activity, 3) change in prednisone dosage, 4) use of new medications for disease activity or hospitalization, and 5) change in Physician's Global Assessment score, a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in SELENA SLEDAI Score at Week 52</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of SELENA SLEDAI Score at Week 52</measure>
    <time_frame>Baseline and every 4 to 8 weeks through Week 52</time_frame>
    <description>SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare. The normalized AUC was created as the ratio of the area under the SELENA SLEDAI score curve divided by baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in British Isles Lupus Activity Group (BILAG) Score at Week 52</measure>
    <time_frame>Baseline, 52 weeks</time_frame>
    <description>The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of BILAG Score at Week 52</measure>
    <time_frame>Baseline and every 4 to 8 weeks through Week 52</time_frame>
    <description>The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.The normalized AUC was created as the ratio of the area under the global BILAG score curve divided by baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Type A/B SLE Flare (as Defined Using BILAG) Over 52 Weeks</measure>
    <time_frame>0 to 52 weeks</time_frame>
    <description>SLE flare indicates an increase in SLE disease activity. An SLE flare was a type A or B SLE flare (as defined using BILAG) compared with the previous visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With a Reduction in Prednisone Dose</measure>
    <time_frame>Baseline, weeks 40 to 52</time_frame>
    <description>Percentage of patients whose average prednisone dose has been reduced by ≥ 50% and/or has been reduced to ≤ 7.5 mg/day during Weeks 40 through 52 in patients receiving greater than 7.5 mg/day at baseline.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events (AE) Overview</measure>
    <time_frame>Up to 84 weeks</time_frame>
    <description>Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 76/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBSL99/NCT00583362).</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">449</enrollment>
  <condition>Lupus Erythematosus, Systemic</condition>
  <arm_group>
    <arm_group_label>Placebo plus SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belimumab 1 mg/kg plus SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belimumab 4 mg/kg plus SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Belimumab 10 mg/kg plus SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.</description>
    <arm_group_label>Placebo plus SOC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belimumab 1 mg/kg</intervention_name>
    <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.</description>
    <arm_group_label>Belimumab 1 mg/kg plus SOC</arm_group_label>
    <other_name>LymphoStat-B®</other_name>
    <other_name>BENLYSTA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belimumab 4 mg/kg</intervention_name>
    <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.</description>
    <arm_group_label>Belimumab 4 mg/kg plus SOC</arm_group_label>
    <other_name>LymphoStat-B®</other_name>
    <other_name>BENLYSTA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belimumab 10 mg/kg</intervention_name>
    <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on belimumab 10 mg/kg for an additional 24 weeks.</description>
    <arm_group_label>Belimumab 10 mg/kg plus SOC</arm_group_label>
    <other_name>LymphoStat-B®</other_name>
    <other_name>BENLYSTA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria

          -  Clinical diagnosis of SLE

          -  &quot;Active&quot; SLE disease

          -  On a stable SLE treatment regimen

          -  History of measurable autoantibodies

        Primary Exclusion Criteria

          -  Received a non-FDA approved investigational agent within last 28 days

          -  Cyclosporin, intravenous immunoglobulin (IVIG) or plasmapheresis within last 90 days

          -  Active lupus nephritis requiring hemodialysis, cyclophosphamide (Cytoxan™), or
             high-dose prednisone (&gt; 100 mg/day) within last 90 days

          -  Active central nervous system (CNS) lupus requiring therapeutic intervention within
             last 60 days

          -  History of renal transplant

          -  History of chronic infection that has been active within last 6 months, herpes zoster
             within last 90 days or any infection requiring hospitalization or intravenous
             medication within last 60 days

          -  History of hypogammaglobulinemia or immunoglobulin A (IgA) deficiency

          -  Human immunodeficiency virus (HIV), Hepatitis B, Hepatitis C
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis Research</name>
      <address>
        <city>Paradise Valley</city>
        <state>Arizona</state>
        <zip>85253</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>LaJolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boling Clinical Trials</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <zip>91730</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCDMC</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817-1418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Care Center, Inc.</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95126-1650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates &amp; Osteoporosis Center Of Colorado Springs</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatic Disease Specialties</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates of Central Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Medical Group, P.A.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research Boise</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Arthritis and Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Medical School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Associates</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Specialists</name>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <zip>46321</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kentuckiana Center for Better Bone and Joint Health</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Osteoporosis and Arthritis Clinical Trial Center</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts--New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0358</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center of Nebraska</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Osteoporosis Center</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <zip>03301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strafford Medical Associates, P.A.</name>
      <address>
        <city>Dover</city>
        <state>New Hampshire</state>
        <zip>03820</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY-Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aair Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7280</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic and Carolina Bone and Joint</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stat Research Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bone and Joint Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Medical Research Foundation</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Center For Arthritis Therapy &amp; Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh School of Medicine &amp; ASPH</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatic Disease Associates</name>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Associates of North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8884</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Research Center</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis and Rheumatic Disease Clinic</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians Research Options, LC</name>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <zip>84070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Clinic of Northern Virginia, P.C.</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edmonds Rheumatology Associates</name>
      <address>
        <city>Edmonds</city>
        <state>Washington</state>
        <zip>98026-8047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Northwest Rheumatology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Clinic, Ltd.</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical College of Wisconsin , Inc</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Medical Research Foundation</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.</citation>
    <PMID>19714604</PMID>
  </results_reference>
  <results_reference>
    <citation>Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698.</citation>
    <PMID>19714615</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2003</study_first_submitted>
  <study_first_submitted_qc>October 27, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2003</study_first_posted>
  <results_first_submitted>February 27, 2012</results_first_submitted>
  <results_first_submitted_qc>July 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2012</results_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SLE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Belimumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Plus SOC</title>
          <description>Placebo IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
        </group>
        <group group_id="P2">
          <title>Belimumab 1 mg/kg Plus SOC</title>
          <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study. The 24-week open-label extension period of the study included patients who completed the 52-week double-blind period and opted to continue to receive the same dose in the 24-week open-label extension period of the study.</description>
        </group>
        <group group_id="P3">
          <title>Belimumab 4 mg/kg Plus SOC</title>
          <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study. The 24-week open-label extension period of the study included patients who completed the 52-week double-blind period and opted to continue to receive the same dose in the 24-week open-label extension period of the study.</description>
        </group>
        <group group_id="P4">
          <title>Belimumab 10 mg/kg Plus SOC</title>
          <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study. The 24 week-open label extension period of the study included patients who completed the 52-week double-blind period and opted to continue in the 24-week open-label period of the study and included patients who were originally randomized to the belimumab 10 mg/kg group in the double-blind period, patients who switched to belimumab 10 mg/kg at the investigator's discretion, and former placebo patients.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>52-Week Double-Blind Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="113"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="111"/>
                <participants group_id="P4" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="87"/>
                <participants group_id="P3" count="94"/>
                <participants group_id="P4" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Compliance</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>24-Week Open-Label Extension Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Of 93: 88 switched to 10 mg/kg; 5 elected not to continue in the open-label extension period.</participants>
                <participants group_id="P2" count="19">Of 87: 65 switched to 10 mg/kg; 3 elected not to continue in the open-label extension period.</participants>
                <participants group_id="P3" count="24">Of 94: 64 switched to 10 mg/kg; 6 elected not to continue in the open-label extension period.</participants>
                <participants group_id="P4" count="302">Of 90: 85 continued with 10 mg/kg; 5 elected not to continue in the open-label extension period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="279"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Plus SOC</title>
          <description>Placebo IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
        </group>
        <group group_id="B2">
          <title>Belimumab 1 mg/kg Plus SOC</title>
          <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
        </group>
        <group group_id="B3">
          <title>Belimumab 4 mg/kg Plus SOC</title>
          <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
        </group>
        <group group_id="B4">
          <title>Belimumab 10 mg/kg Plus SOC</title>
          <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="113"/>
            <count group_id="B2" value="114"/>
            <count group_id="B3" value="111"/>
            <count group_id="B4" value="111"/>
            <count group_id="B5" value="449"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" spread="10.9"/>
                    <measurement group_id="B2" value="42.0" spread="11.7"/>
                    <measurement group_id="B3" value="42.6" spread="10.7"/>
                    <measurement group_id="B4" value="41.8" spread="11.7"/>
                    <measurement group_id="B5" value="42.2" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="105"/>
                    <measurement group_id="B4" value="105"/>
                    <measurement group_id="B5" value="419"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="109"/>
                    <measurement group_id="B5" value="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change From Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24.</title>
        <description>SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare.</description>
        <time_frame>Baseline, 24 weeks</time_frame>
        <population>Analysis was performed on a modified intention-to-treat (MITT) population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index (SELENA SLEDAI) Score at Week 24.</title>
          <description>SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare.</description>
          <population>Analysis was performed on a modified intention-to-treat (MITT) population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.2" spread="5.1"/>
                    <measurement group_id="O2" value="-23.3" spread="4.4"/>
                    <measurement group_id="O3" value="-11.3" spread="5.4"/>
                    <measurement group_id="O4" value="-23.7" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using a last observation carried forward (LOCF) imputation. If patient required a protocol-prohibited medication, the SELENA SLEDAI score of the last visit prior to the use of the prohibited medication was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3677</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.4</ci_lower_limit>
            <ci_upper_limit>7.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using LOCF imputation. If patient required a protocol-prohibited medication, the SELENA SLEDAI score of the last visit prior to the use of the prohibited medication was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4244</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.7</ci_lower_limit>
            <ci_upper_limit>20.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using LOCF imputation. If patient required a protocol-prohibited medication, the SELENA SLEDAI score of the last visit prior to the use of the prohibited medication was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3296</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.6</ci_lower_limit>
            <ci_upper_limit>6.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to First Mild/Moderate or Severe SLE Flare (SLE Flare Index)</title>
        <description>The SLE Flare Index categorized SLE flare as &quot;mild or moderate&quot; or &quot;severe&quot; based on 5 variables: 1) change in SELENA SLEDAI score from the most recent assessment to current, 2) change in signs or symptoms of disease activity, 3) change in prednisone dosage, 4) use of new medications for disease activity or hospitalization, and 5) change in Physician's Global Assessment score, a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe).</description>
        <time_frame>0 to 52 weeks</time_frame>
        <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Mild/Moderate or Severe SLE Flare (SLE Flare Index)</title>
          <description>The SLE Flare Index categorized SLE flare as &quot;mild or moderate&quot; or &quot;severe&quot; based on 5 variables: 1) change in SELENA SLEDAI score from the most recent assessment to current, 2) change in signs or symptoms of disease activity, 3) change in prednisone dosage, 4) use of new medications for disease activity or hospitalization, and 5) change in Physician's Global Assessment score, a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe).</description>
          <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="42" upper_limit="140"/>
                    <measurement group_id="O2" value="68" lower_limit="39" upper_limit="146"/>
                    <measurement group_id="O3" value="61" lower_limit="29" upper_limit="147"/>
                    <measurement group_id="O4" value="70" lower_limit="29" upper_limit="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Patients who required protocol-prohibited medications were considered to have a flare on the date the prohibited medication was started or date of the first flare, whichever came first. Patients who withdrew from the study for reasons other than SLE disease manifestations or hospitalization related to SLE or who missed 2 or more consecutive visits were censored at the time of the last assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6423</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patients who required protocol-prohibited medications were considered to have a flare on the date the prohibited medication was started or date of the first flare, whichever came first. Patients who withdrew from the study for reasons other than SLE disease manifestations or hospitalization related to SLE or who missed 2 or more consecutive visits were censored at the time of the last assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8536</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Patients who required protocol-prohibited medications were considered to have a flare on the date the prohibited medication was started or date of the first flare, whichever came first. Patients who withdrew from the study for reasons other than SLE disease manifestations or hospitalization related to SLE or who missed 2 or more consecutive visits were censored at the time of the last assessment.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9705</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in SELENA SLEDAI Score at Week 52</title>
        <description>SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in SELENA SLEDAI Score at Week 52</title>
          <description>SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare</description>
          <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.6" spread="5.2"/>
                    <measurement group_id="O2" value="-29.7" spread="4.3"/>
                    <measurement group_id="O3" value="-23.9" spread="7.3"/>
                    <measurement group_id="O4" value="-27.9" spread="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using LOCF imputation. If patient required a protocol-prohibited medication, the SELENA SLEDAI score of the last visit prior to the use of the prohibited medication was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1763</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.4</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using LOCF imputation. If patient required a protocol-prohibited medication, the SELENA SLEDAI score of the last visit prior to the use of the prohibited medication was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7112</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.9</ci_lower_limit>
            <ci_upper_limit>14.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using LOCF imputation. If patient required a protocol-prohibited medication, the SELENA SLEDAI score of the last visit prior to the use of the prohibited medication was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3320</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.2</ci_lower_limit>
            <ci_upper_limit>7.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) of SELENA SLEDAI Score at Week 52</title>
        <description>SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare. The normalized AUC was created as the ratio of the area under the SELENA SLEDAI score curve divided by baseline score.</description>
        <time_frame>Baseline and every 4 to 8 weeks through Week 52</time_frame>
        <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of SELENA SLEDAI Score at Week 52</title>
          <description>SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores &gt; 20 are rare. The normalized AUC was created as the ratio of the area under the SELENA SLEDAI score curve divided by baseline score.</description>
          <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
          <units>ratio score*days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="317.3" spread="14.0"/>
                    <measurement group_id="O2" value="288.7" spread="12.5"/>
                    <measurement group_id="O3" value="320.3" spread="14.0"/>
                    <measurement group_id="O4" value="286.9" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using LOCF imputation. If patient required a protocol-prohibited medication, the SELENA SLEDAI score of the last visit prior to the use of the prohibited medication was used.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1287</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-28.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.6</ci_lower_limit>
            <ci_upper_limit>8.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using LOCF imputation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8807</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.2</ci_lower_limit>
            <ci_upper_limit>42.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Missing data was handled by using LOCF imputation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1131</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-30.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-68.1</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in British Isles Lupus Activity Group (BILAG) Score at Week 52</title>
        <description>The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.</description>
        <time_frame>Baseline, 52 weeks</time_frame>
        <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in British Isles Lupus Activity Group (BILAG) Score at Week 52</title>
          <description>The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.</description>
          <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.1" spread="4.3"/>
                    <measurement group_id="O2" value="-20.8" spread="4.3"/>
                    <measurement group_id="O3" value="-26.5" spread="3.4"/>
                    <measurement group_id="O4" value="-22.0" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Missing data for BILAG were handled as described previously for SELENA SLEDAI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7823</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.8</ci_lower_limit>
            <ci_upper_limit>10.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Missing data for BILAG were handled as described previously for SELENA SLEDAI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1774</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.2</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Missing data for BILAG were handled as described previously for SELENA SLEDAI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6406</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>P-value was not adjusted for multiple testing.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.8</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) of BILAG Score at Week 52</title>
        <description>The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.The normalized AUC was created as the ratio of the area under the global BILAG score curve divided by baseline score.</description>
        <time_frame>Baseline and every 4 to 8 weeks through Week 52</time_frame>
        <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) of BILAG Score at Week 52</title>
          <description>The BILAG index is a clinical measure of lupus disease activity. BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E). The global BILAG score is the sum of the numerical scores in the 8 domains assigning A=9, B=3, C=1, D=0, E=0.The normalized AUC was created as the ratio of the area under the global BILAG score curve divided by baseline score.</description>
          <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
          <units>ratio score*days</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315.4" spread="12.3"/>
                    <measurement group_id="O2" value="310.6" spread="12.0"/>
                    <measurement group_id="O3" value="300.4" spread="9.3"/>
                    <measurement group_id="O4" value="302.7" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Missing data for BILAG were handled as described previously for SELENA SLEDAI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7822</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38.6</ci_lower_limit>
            <ci_upper_limit>29.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Missing data for BILAG were handled as described previously for SELENA SLEDAI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3332</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-45.3</ci_lower_limit>
            <ci_upper_limit>15.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Missing data for BILAG were handled as described previously for SELENA SLEDAI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4660</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-46.9</ci_lower_limit>
            <ci_upper_limit>21.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Type A/B SLE Flare (as Defined Using BILAG) Over 52 Weeks</title>
        <description>SLE flare indicates an increase in SLE disease activity. An SLE flare was a type A or B SLE flare (as defined using BILAG) compared with the previous visit.</description>
        <time_frame>0 to 52 weeks</time_frame>
        <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Type A/B SLE Flare (as Defined Using BILAG) Over 52 Weeks</title>
          <description>SLE flare indicates an increase in SLE disease activity. An SLE flare was a type A or B SLE flare (as defined using BILAG) compared with the previous visit.</description>
          <population>Analysis was performed on a MITT population, defined as all patients who were randomized and received at least 1 dose of study agent.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" lower_limit="34" upper_limit="138"/>
                    <measurement group_id="O2" value="63" lower_limit="54" upper_limit="110"/>
                    <measurement group_id="O3" value="84" lower_limit="51" upper_limit="139"/>
                    <measurement group_id="O4" value="62" lower_limit="33" upper_limit="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Missing data for BILAG were handled as described previously for SELENA SLEDAI (SLE Flare Index).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5615</p_value>
            <p_value_desc>P-value was not adjusted for multiple comparisons.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Missing data for BILAG were handled as described previously for SELENA SLEDAI (SLE Flare Index).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7593</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Missing data for BILAG were handled as described previously for SELENA SLEDAI (SLE Flare Index).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2273</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With a Reduction in Prednisone Dose</title>
        <description>Percentage of patients whose average prednisone dose has been reduced by ≥ 50% and/or has been reduced to ≤ 7.5 mg/day during Weeks 40 through 52 in patients receiving greater than 7.5 mg/day at baseline.</description>
        <time_frame>Baseline, weeks 40 to 52</time_frame>
        <population>Analysis was performed on a subgroup of the MITT population, which included only patients with baseline prednisone dose &gt; 7.5 mg/day.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Reduction in Prednisone Dose</title>
          <description>Percentage of patients whose average prednisone dose has been reduced by ≥ 50% and/or has been reduced to ≤ 7.5 mg/day during Weeks 40 through 52 in patients receiving greater than 7.5 mg/day at baseline.</description>
          <population>Analysis was performed on a subgroup of the MITT population, which included only patients with baseline prednisone dose &gt; 7.5 mg/day.</population>
          <units>percentatge of particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="31.4"/>
                    <measurement group_id="O4" value="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Patients who dropped out or had missing data were considered failures.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4355</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Likelihood ratio chi-squared</method>
            <param_type>percent difference from placebo</param_type>
            <param_value>-7.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.7</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Patients who dropped out or had missing data were considered failures.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6669</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Likelihood ratio chi-squared</method>
            <param_type>percent difference from placebo</param_type>
            <param_value>4.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.5</ci_lower_limit>
            <ci_upper_limit>24.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Patients who dropped out or had missing data were considered failures.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0882</p_value>
            <p_value_desc>P-value was not adjusted for multiple testing.</p_value_desc>
            <method>Likelihood ratio chi-squared</method>
            <param_type>percent difference from placebo</param_type>
            <param_value>17.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.5</ci_lower_limit>
            <ci_upper_limit>37.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Events (AE) Overview</title>
        <description>Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 76/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBSL99/NCT00583362).</description>
        <time_frame>Up to 84 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo Plus SOC</title>
            <description>Placebo IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O2">
            <title>Belimumab 1 mg/kg Plus SOC</title>
            <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O3">
            <title>Belimumab 4 mg/kg Plus SOC</title>
            <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O4">
            <title>Belimumab 10 mg/kg Plus SOC</title>
            <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study.</description>
          </group>
          <group group_id="O5">
            <title>Open-Label Extension Period: All Active</title>
            <description>Includes all patients who completed the 52-week double-blind period and opted to continue in a 24-week open-label extension period. Belimumab patients received the same dose or were switched to belimumab 10 mg/kg at the investigator's discretion and former placebo patients received belimumab 10 mg/kg. AE onset may be during the extension phase or continuing from the double-blind period.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AE) Overview</title>
          <description>Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 76/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBSL99/NCT00583362).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="111"/>
                <count group_id="O5" value="345"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent of patients with at least 1 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3"/>
                    <measurement group_id="O2" value="97.4"/>
                    <measurement group_id="O3" value="96.4"/>
                    <measurement group_id="O4" value="97.3"/>
                    <measurement group_id="O5" value="96.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent of patients with at least 1 SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5"/>
                    <measurement group_id="O2" value="18.4"/>
                    <measurement group_id="O3" value="13.5"/>
                    <measurement group_id="O4" value="16.2"/>
                    <measurement group_id="O5" value="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent of patients with an AE resulting in death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0.9"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 84 weeks</time_frame>
      <desc>Includes AEs reported in patients from the first dose of study agent throughout the study up to the Week 76/exit visit or 8 weeks following the last dose of study agent for patients who withdrew from this study or decided not to participate in the optional continuation protocol (LBSL99/NCT00583362).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo Plus SOC</title>
          <description>Placebo IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study</description>
        </group>
        <group group_id="E2">
          <title>Belimumab 1 mg/kg Plus SOC</title>
          <description>Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study</description>
        </group>
        <group group_id="E3">
          <title>Belimumab 4 mg/kg Plus SOC</title>
          <description>Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study</description>
        </group>
        <group group_id="E4">
          <title>Belimumab 10 mg/kg Plus SOC</title>
          <description>Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE for 52-week double-blind period of the study</description>
        </group>
        <group group_id="E5">
          <title>Open-label Extension Period: All Active</title>
          <description>Includes all patients who completed the 52-week double-blind period and opted to continue in a 24-week open-label extension period. Belimumab patients received the same dose or were switched to 10 mg/kg at investigator discretion and former placebo patients received belimumab 10 mg/kg. AE onset may be during the extension phase or continuing from the double-blind period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Aplastic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Haemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pericarditis lupus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pleuropericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Appendicitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastroenteritis noninfectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adhesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Bronchitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Septic arthritis streptobacillus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Streptococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>West Nile viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Spondylosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Metastases to bone marrow</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Simple partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Lupus nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Vulvar dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Chronic obstructive airways disease exacerbated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Dyspnoea exacerbated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioneurotic oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Post procedural drainage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 7.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="103" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="107" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="100" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="105" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="312" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="72" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Infusion site reaction</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Vaginal mycosis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="102" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="47" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="42" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="34" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>SLE arthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="35" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="345"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="345"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

